By InvitationPhase 3

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

United States700 participantsStarted 2024-12-03

Plain-language summary

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003 Exclusion Criteria: * Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003 * Future or current participation in another investigational device or drug study, scheduled to occur during this study * Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation

What they're measuring

Frequency of Adverse Events (AEs)

Timeframe: Up to 36 Months

Trial details

NCT IDNCT06679946

SponsorAlnylam Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-03-31

View on ClinicalTrials.gov More Transthyretin Amyloidosis (ATTR) With Cardiomyopathy trials